Sarepta's stock drops on ELEVIDYS safety concerns, yet potential remains for ambulatory patients. Click here to read an ...

Despite setbacks, Sarepta’s gene therapy pipeline and market leadership in DMD present a high-risk, high-reward setup. Read ...

Shares of Sarepta Therapeutics closed down as much as 42% to hit a nine-year low of $18.30 on Monday after a second death of ...

Sarepta Therapeutics shares sank to their lowest level in nine years Monday after a second patient taking its Elevidys drug ...

Sarepta Therapeutics said a second patient had died after receiving its $3.2 million gene therapy to treat Duchenne muscular ...

WASHINGTON (AP) — Shares of Sarepta Therapeutics plunged Monday after the biotech drugmaker reported a second death in ...

Shares in both companies were down following news of the second death, casting fresh safety concerns over Elevidys.

The death of a boy with Duchenne muscular dystrophy, tied to a gene therapy, is above all a tragedy. But it is also ...

Fintel reports that on June 17, 2025, Morgan Stanley downgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) from ...

Fintel reports that on June 17, 2025, Goldman Sachs downgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) from ...

Sarepta Therapeutics Inc. said a second patient has died of acute liver failure after being treated with its gene therapy for ...

Shares of Sarepta Therapeutics, Inc. SRPT fell sharply in today's pre-market trading after the company suspended ELEVIDYS ...